Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A

Trial Profile

Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2019

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Diabetic cardiomyopathy; Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Acronyms RECOGITO
  • Most Recent Events

    • 09 Jul 2019 Status changed from recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 27 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top